Form 4: Vir Biotechnology EVP Vanina de Verneuil Reports Stock Sale

Vanina de Verneuil, EVP and General Counsel of Vir Biotechnology, sold 4,397 shares of common stock at a price of $10.11 on November 6, 2024, according to a Form 4 filing.

Summary

• On November 6, 2024, Vanina de Verneuil, the EVP and General Counsel of Vir Biotechnology, sold 4,397 shares of common stock.
• The sale was executed at a price of $10.11 per share.
• Following the transaction, de Verneuil directly owns 56,973 shares of Vir Biotechnology.
• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on August 5, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports a routine stock sale by an executive under a pre-arranged trading plan. It doesn't inherently indicate positive or negative prospects for the company.

Industry Context

Executive stock sales are a common occurrence and are often related to personal financial planning. The use of a 10b5-1 trading plan suggests the sale was pre-planned and not based on inside information.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.

Key Dates